Vanguard Group Inc Avalo Therapeutics, Inc. Transaction History

Vanguard Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$3.15 - $808.8 $9.67 Million - $2.48 Billion	-3,070,553 Closed	0 $0
Q2 2022 Aug 12, 2022	SELL	$3.0 - $10.45 $940,923 - $3.28 Million	-313,641 Reduced 9.27%	3,070,553 $1.54 Million
Q1 2022 May 13, 2022	BUY	$7.57 - $21.72 $37,024 - $106,232	4,891 Added 0.14%	3,384,194 $2.45 Million
Q4 2021 Feb 14, 2022	BUY	$19.68 - $28.68 $630,291 - $918,534	32,027 Added 0.96%	3,379,303 $5.74 Million
Q3 2021 Nov 12, 2021	BUY	$26.16 - $40.68 $87.6 Million - $136 Million	3,347,276 New	3,347,276 $7.3 Million

34.6K

Ticker AVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,414,100
Market Cap $91.1M
Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.